pubmed-article:12140804 | rdf:type | pubmed:Citation | lld:pubmed |
pubmed-article:12140804 | lifeskim:mentions | umls-concept:C0008976 | lld:lifeskim |
pubmed-article:12140804 | lifeskim:mentions | umls-concept:C0018801 | lld:lifeskim |
pubmed-article:12140804 | lifeskim:mentions | umls-concept:C0025664 | lld:lifeskim |
pubmed-article:12140804 | lifeskim:mentions | umls-concept:C1707689 | lld:lifeskim |
pubmed-article:12140804 | lifeskim:mentions | umls-concept:C2699007 | lld:lifeskim |
pubmed-article:12140804 | pubmed:issue | 3 | lld:pubmed |
pubmed-article:12140804 | pubmed:dateCreated | 2002-7-25 | lld:pubmed |
pubmed-article:12140804 | pubmed:abstractText | Hydralazine and isosorbide dinitrate combination (H+ISDN), angiotensin-converting enzyme inhibitors, and beta-blockers have improved outcomes in heart failure (HF). Analysis of previous trials has shown that H+ISDN appears especially beneficial in African American patients. | lld:pubmed |
pubmed-article:12140804 | pubmed:language | eng | lld:pubmed |
pubmed-article:12140804 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:12140804 | pubmed:citationSubset | IM | lld:pubmed |
pubmed-article:12140804 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:12140804 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:12140804 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:12140804 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:12140804 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:12140804 | pubmed:status | MEDLINE | lld:pubmed |
pubmed-article:12140804 | pubmed:month | Jun | lld:pubmed |
pubmed-article:12140804 | pubmed:issn | 1071-9164 | lld:pubmed |
pubmed-article:12140804 | pubmed:author | pubmed-author:LoscalzoJosep... | lld:pubmed |
pubmed-article:12140804 | pubmed:author | pubmed-author:YancyClyde... | lld:pubmed |
pubmed-article:12140804 | pubmed:author | pubmed-author:CohnJay NJN | lld:pubmed |
pubmed-article:12140804 | pubmed:author | pubmed-author:OfiliElizabet... | lld:pubmed |
pubmed-article:12140804 | pubmed:author | pubmed-author:WorcelManuelM | lld:pubmed |
pubmed-article:12140804 | pubmed:author | pubmed-author:FranciosaJose... | lld:pubmed |
pubmed-article:12140804 | pubmed:author | pubmed-author:TaylorAnne... | lld:pubmed |
pubmed-article:12140804 | pubmed:author | pubmed-author:ZiescheSusanS | lld:pubmed |
pubmed-article:12140804 | pubmed:author | pubmed-author:OlukotunAdeoy... | lld:pubmed |
pubmed-article:12140804 | pubmed:author | pubmed-author:FerdinandKeit... | lld:pubmed |
pubmed-article:12140804 | pubmed:author | pubmed-author:A-HeFT... | lld:pubmed |
pubmed-article:12140804 | pubmed:issnType | Print | lld:pubmed |
pubmed-article:12140804 | pubmed:volume | 8 | lld:pubmed |
pubmed-article:12140804 | pubmed:owner | NLM | lld:pubmed |
pubmed-article:12140804 | pubmed:authorsComplete | Y | lld:pubmed |
pubmed-article:12140804 | pubmed:pagination | 128-35 | lld:pubmed |
pubmed-article:12140804 | pubmed:dateRevised | 2007-11-15 | lld:pubmed |
pubmed-article:12140804 | pubmed:meshHeading | pubmed-meshheading:12140804... | lld:pubmed |
pubmed-article:12140804 | pubmed:meshHeading | pubmed-meshheading:12140804... | lld:pubmed |
pubmed-article:12140804 | pubmed:meshHeading | pubmed-meshheading:12140804... | lld:pubmed |
pubmed-article:12140804 | pubmed:meshHeading | pubmed-meshheading:12140804... | lld:pubmed |
pubmed-article:12140804 | pubmed:meshHeading | pubmed-meshheading:12140804... | lld:pubmed |
pubmed-article:12140804 | pubmed:meshHeading | pubmed-meshheading:12140804... | lld:pubmed |
pubmed-article:12140804 | pubmed:meshHeading | pubmed-meshheading:12140804... | lld:pubmed |
pubmed-article:12140804 | pubmed:meshHeading | pubmed-meshheading:12140804... | lld:pubmed |
pubmed-article:12140804 | pubmed:meshHeading | pubmed-meshheading:12140804... | lld:pubmed |
pubmed-article:12140804 | pubmed:meshHeading | pubmed-meshheading:12140804... | lld:pubmed |
pubmed-article:12140804 | pubmed:meshHeading | pubmed-meshheading:12140804... | lld:pubmed |
pubmed-article:12140804 | pubmed:meshHeading | pubmed-meshheading:12140804... | lld:pubmed |
pubmed-article:12140804 | pubmed:meshHeading | pubmed-meshheading:12140804... | lld:pubmed |
pubmed-article:12140804 | pubmed:meshHeading | pubmed-meshheading:12140804... | lld:pubmed |
pubmed-article:12140804 | pubmed:meshHeading | pubmed-meshheading:12140804... | lld:pubmed |
pubmed-article:12140804 | pubmed:meshHeading | pubmed-meshheading:12140804... | lld:pubmed |
pubmed-article:12140804 | pubmed:meshHeading | pubmed-meshheading:12140804... | lld:pubmed |
pubmed-article:12140804 | pubmed:meshHeading | pubmed-meshheading:12140804... | lld:pubmed |
pubmed-article:12140804 | pubmed:meshHeading | pubmed-meshheading:12140804... | lld:pubmed |
pubmed-article:12140804 | pubmed:year | 2002 | lld:pubmed |
pubmed-article:12140804 | pubmed:articleTitle | African-American Heart Failure Trial (A-HeFT): rationale, design, and methodology. | lld:pubmed |
pubmed-article:12140804 | pubmed:affiliation | Zena and Michael A. Wiener Cardiovascular Institute, Mt. Sinai School of Medicine, New York, New York, USA. | lld:pubmed |
pubmed-article:12140804 | pubmed:publicationType | Journal Article | lld:pubmed |
pubmed-article:12140804 | pubmed:publicationType | Clinical Trial | lld:pubmed |
pubmed-article:12140804 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
pubmed-article:12140804 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:12140804 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:12140804 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:12140804 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:12140804 | lld:pubmed |